Antisense, RNA

Antisense, RNA Companies (9)

Antisense, RNA News

Antisense, RNA Products (14)

  • Product Oligonucleotide CRDMO Platform

    WuXi TIDES has a robust and integrated Oligo API Platform, offering R&D and manufacturing services from preclinical to commercial scale and operating out of our US FDA inspected facility based in Changzhou, China. We support the development and manufacture of a variety of oligonucleotide modalities inc...
  • Product Oligonucleotide Analytical Development Services

    Analytical development services for oligonucleotides: For oligo-based drugs, our capabilities range from GLP bioanalysis to GLP/cGMP characterisation. We support product development, from quality control testing of amidite starting materials and early stage product characterization through to GMP batch r...
  • Product Bespoke Oligonucleotide Synthesis Service and Partnerships

    Whether you need a single sequence for a project or are looking for a long-term collaborative partner, we synthesize and deliver the best DNA/RNA oligonucleotides for your precise needs. Oligonucleotides are the backbone of molecular diagnostics and the future of personalised medicine. We synthesize and d...
  • Product 1 GHz NMR

    New Evo 1 GHz NMR fits in 1 story building, uses 70% less helium. Ideally suited to characterise complex molecules such as RNA, oligonucleotides, peptides, antibodies and more!
  • Product CordenPharma Lipid Data Sheet > C12-200

    • Chemical name: 1,1‘-((2-(4-(2-((2-(bis(2-hydroxydodecyl)amino)ethyl)(2-hydroxydodecyl)amino)ethyl)piperazin-1-yl)ethyl)azanediyl)bis(dodecan-2-ol) Application: Lipid NanoParticles as delivery systems for enabling the therapeutic potential of siRNA, mRNA or CRISPR as they exhibit remarkable in ...
  • Product Oligonucleotides

    Sumitomo Chemical has unique manufacturing technology for long (more than 100-mer) oligonucleotides with purity of 90%
  • Product Large Molecule Discovery & Development Services

    We provide a wide range of discovery and development services for New Biological Entities (NBEs) from our state-of-the-art facility located in Hyderabad, India. At the core of NBE services is a talented team of scientists experienced in the design and delivery of a range of advanced therapeutic modalities ...
  • Product 2-OMOE-phosphoramidites

    used for oligonucleotides systhesis
  • Product Generic / Monomer

    1. Generic ST Pharm focusing on technical challenging and brand generics. We specialize in MRI contrast agents and and possess a portfolio of tuberculosis and anti-infectious drugs as generic APIs. 2. Monomer ST Pharm offers a one-stop service from nucleosides to phosphoramidites with specialty and commo...
  • Product mRNA Characterisation and Analysis

    Characterization and analysis of mRNA supporting vaccine and therapeutic development, including assessing clinical translation efficiency and immunogenicity. At our GLP / GCP / GMP laboratories, scientists can test a mRNA drug substance or drug product to help you confidently assess batch to batch manufa...
  • Product CordenPharma BotaniChol® Plant-Based Cholesterol

    Chemists at CordenPharma and the Otto-von-Guericke-University of Magdeburg, Germany developed a scalable synthesis of pharma-grade cholesterol based on botanical sources. This offers a large-scale production of highly needed cholesterol, which is used as part of the lipid cocktail ...
  • Product Oligonucleotide CDMO

    ST Pharm offers top-tier customized oligonucleotide CDMO services under stringent cGMP conditions. We enhance raw material supply chain resilience by leveraging in-house manufacturing capabilities of nucleosides/phosphormaidites. Our two state-of-the-art facilities, expected to reach a 7.0 mol capacity b...
  • Product Oligo Synthesis

    • Unlabeled oligos • Custom DNA oligos • Custom RNA oligos • qPCR primer and Probe • siRNA, sgRNA, crRNA, ASO etc.
  • Product ATB-301

    [TGF-β2 Targeting ASO (TASO) + IL-2 Combination therapy] - Phase Ib

    1. Confirm the potential of TGF-β2 as a biomarker in human blood and tumor tissues from the efficacy result of Phase Ib clinical trial on cancer patients 

    2. Confirm the suppression of IL-2’s side effect in combinati...

Upcoming Events

  • CPHI Middle East 2024

    Riyadh Front Exhibition & Convention Center Riyadh, Saudi Arabia
    10 Dec 2024 - 12 Dec 2024
  • Pharmapack Europe 2025

    Paris Expo, Porte de Versailles - Hall 7.2 | Paris, France
    22 Jan 2025 - 23 Jan 2025
  • CPHI Japan 2025

    East Halls 4, 5 & 6, Tokyo Big Sight, Tokyo, Japan
    09 Apr 2025 – 11 Apr 2025

Pharmaceutical Industry Webinars